Journal
CANCER LETTERS
Volume 491, Issue -, Pages 11-21Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2020.07.024
Keywords
Minicells; Drug delivery; Cancer therapy; Bispecific antibody; Chemotherapeutic
Categories
Funding
- National Natural Science Foundation of China [31970874]
- Chongqing Natural Science Foundation [csct2018jcyjA1294]
- Fundamental Research Funds for the Central Universities [SWU117062, SWU117061]
Ask authors/readers for more resources
Bacteria are always a considerable tool for the cancer therapy. The bacteria-derived minicells are re-emerged as a promising drug delivery system for cancer therapy. The minicells are nano-sized, anucleated, non-dividing, and metabolically active cells produced by abnormal bacterial cell division that are able to transcribe and translate the gene of interest. Minicells encapsulate a wide range of chemotherapeutic and molecular drugs, si/shRNA, antigens and therapeutic toxins to precisely deliver them to the cancer cells through the easy modification of minicell surface with bi-specific antibodies against receptor-targeted cancer cells. Minicell-mediated chemotherapy may inhibit the growth of drug-resistant tumors and exhibits the potential to successfully deliver the chemotherapeutics into hypoxic and necrotic region in solid tumors. This novel approach significantly overcomes drug leakage and severe toxicity by enhancing targeting specificity and therapeutic index of drugs in cancer therapy. Many antibody-conjugated drug-loaded minicells are being investigated in clinical trials for cancer therapy. This review summarizes the advantages of bacteria-derived minicells as delivery systems for anti-cancer drugs or agents and the recent advances and emerging future in cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available